Cipla shares slide 4.5% after USFDA flags compliance gaps at key Lanreotide supplier site

Cipla shares fall 4% as partner gets US FDA observations

• Cipla shares drop 4% after US FDA flags Pharmathen compliance issues
• FDA cites contamination risks, poor sterile manufacturing at Pharmathen facility
• Lanreotide injection, key Cipla product, faces scrutiny after FDA inspection

Did our AI summary help?

Cipla shares fell sharply after the U.S. Food and Drug Administration (USFDA) flagged multiple compliance lapses at Pharmathen International SA, the third party contract manufacturer that supplies the drugmaker’s key generic Lanreotide injection for the US market.

The stock declined as much as 4.5% in Mumbai trading on January 7, reflecting investor concerns that regulatory action at Pharmathen’s main manufacturing site in Greece could potentially disrupt supplies of one of Cipla’s important complex injectables.

The USFDA inspection, which concluded in November 2025, resulted in the issuance of a Form 483 to Pharmathen’s Sapes, Rodopi facility—its largest plant and a critical hub for long‑acting injectables, sustained‑release products and preservative‑free ophthalmics sold in the US. The regulator cited gaps in contamination controls, aseptic processes, laboratory procedures and building conditions, among other observations.

While a Form 483 does not immediately halt production, it signals regulatory shortcomings that must be addressed through corrective and preventive action plans to avoid escalation. Still, the nature of the observations has heightened market concerns given the facility’s importance to Cipla’s US supply chain.

According to IQVIA data cited by the company, Somatuline Depot recorded about $898 million in U.S. sales in the 12 months ended March 2024, underlining the commercial significance of the opportunity. Cipla is the first generic and has limited competition for this product. Any prolonged disruption or regulatory escalation at Pharmathen could therefore delay Cipla’s ability to scale the launch or maintain consistent supply.

The regulatory scrutiny comes after Cipla secured final USFDA approval in May 2024 for for Lanreotide Injection, a complex, AP‑rated (therapeutically equivalent to its brand-name counterpart) generic version of Ipsen’s Somatuline Depot used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors. Cipla relies on Pharmathen as its third‑party manufacturer for the product in the US market.

Analysts noted that while the long‑term impact will depend on the speed and effectiveness of Pharmathen’s remediation efforts, the development has weighed on near‑term investor sentiment, particularly given Cipla’s growing exposure to complex injectables in the US.